A. Meerveld-Eggink

886 total citations
20 papers, 283 citations indexed

About

A. Meerveld-Eggink is a scholar working on Surgery, Oncology and Epidemiology. According to data from OpenAlex, A. Meerveld-Eggink has authored 20 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in A. Meerveld-Eggink's work include Respiratory viral infections research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Influenza Virus Research Studies (4 papers). A. Meerveld-Eggink is often cited by papers focused on Respiratory viral infections research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Influenza Virus Research Studies (4 papers). A. Meerveld-Eggink collaborates with scholars based in Netherlands, United Kingdom and United States. A. Meerveld-Eggink's co-authors include Ger T. Rijkers, Douwe H. Biesma, Okke de Weerdt, Heleen van Velzen‐Blad, Ankie M.T. van der Velden, Annette W.G. van der Velden, Matthijs Westerman, Marten R. Nijziel, Aart Beeker and Maartje Los and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

A. Meerveld-Eggink

19 papers receiving 277 citations

Peers

Countries citing papers authored by A. Meerveld-Eggink

Since Specialization

Citations

This map shows the geographic impact of A. Meerveld-Eggink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Meerveld-Eggink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Meerveld-Eggink more than expected).

Fields of papers citing papers by A. Meerveld-Eggink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Meerveld-Eggink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Meerveld-Eggink. The network helps show where A. Meerveld-Eggink may publish in the future.

Co-authorship network of co-authors of A. Meerveld-Eggink

This figure shows the co-authorship network connecting the top 25 collaborators of A. Meerveld-Eggink. A scholar is included among the top collaborators of A. Meerveld-Eggink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Meerveld-Eggink. A. Meerveld-Eggink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands 2023 ·SHILAP Revista de lepidopterología ·Maartje W. Rohaan, (unknown), Lot A. Devriese, A. Meerveld-Eggink, (unknown), Johannes V. van Thienen, Sofie Wilgenhof, Carla M.L. van Herpen, John B.A.G. Haanen	2
2	Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study 2023 ·Clinical Genitourinary Cancer ·(unknown), (unknown), A. Meerveld-Eggink, Francesca Jackson‐Spence, Kathrine S Rallis, Paul Brian, (unknown), Christopher C.T. Sng, (unknown), (unknown), (unknown), Naomi Anderson, Axel Bex, Thomas Powles, Balaji Venugopal, Bernadett Szabados	2
3	854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI) 2022 ·Annals of Oncology ·Judith M. Versluis, (unknown), (unknown), Sofie Wilgenhof, A. Meerveld-Eggink, Henk Mallo, Wilma Uyterlinde, J. Lijnsvelt, J.B.A.G. Haanen, (unknown)	1
4	Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment 2022 ·European Urology Open Science ·A. Meerveld-Eggink, Niels M. Graafland, Sofie Wilgenhof, Johannes V. van Thienen, Ferry Lalezari, (unknown), Bernadett Szabados, Yasmin Abu‐Ghanem, Teele Kuusk, Ekaterini Boleti, Christian U. Blank, John B.A.G. Haanen, Thomas Powles, Axel Bex	20
5	Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series. 2022 ·Journal of Clinical Oncology ·(unknown), (unknown), Serigne Lo, Tasnia Ahmed, Sheima Farag, Nadia Yousaf, Kate Young, (unknown), A. Meerveld-Eggink, Christian U. Blank, (unknown), Jennifer L. McQuade, Bastian Schilling, Douglas B. Johnson, (unknown), Ana Arance, (unknown), Lisa Zimmer, Georgina V. Long, Alexander M. Menzies	0
6	737P Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place 2020 ·Annals of Oncology ·A. Meerveld-Eggink, Niels M. Graafland, Sofie Wilgenhof, Johannes V. van Thienen, (unknown), Bernadett Szabados, Yasmin Abu‐Ghanem, Ekaterini Boleti, Christian U. Blank, John B.A.G. Haanen, T.B. Powles, Axel Bex	1
7	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience 2017 ·Annals of Oncology ·A. Meerveld-Eggink, Elisa A. Rozeman, Ferry Lalezari, Johannes V. van Thienen, J.B.A.G. Haanen, Christian U. Blank	11
8	Persistent changes in circulating white blood cell populations after splenectomy 2017 ·International Journal of Hematology ·Minke A.E. Rab, A. Meerveld-Eggink, Heleen van Velzen‐Blad, Douwe van Loon, Ger T. Rijkers, Okke de Weerdt	14
9	Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy 2017 ·Vaccine ·M.L. Wumkes, Ankie M.T. van der Velden, Erwin de Bruin, A. Meerveld-Eggink, Marion Koopmans, Guus F. Rimmelzwaan, Ger T. Rijkers, Douwe H. Biesma	6
10	Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours 2013 ·Vaccine ·M.L. Wumkes, Ankie M.T. van der Velden, Maartje Los, Mark Leys, Aart Beeker, Marten R. Nijziel, Annette W.G. van der Velden, Matthijs Westerman, A. Meerveld-Eggink, G.F. Rimmelzwaan, Ger T. Rijkers, Douwe H. Biesma	36
11	[Bone metastases or an insufficiency fracture? Oncology patients reporting pain or showing bone abnormalities on a scan]. 2013 ·PubMed ·A. Meerveld-Eggink, Thomas L. Bollen, Harm K. Wijrdeman, Maartje Los	3
12	Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice. 2013 ·PubMed ·M.L. Wumkes, Ankie M.T. van der Velden, Annette W.G. van der Velden, Jacqueline M. Stouthard, Marten R. Nijziel, Matthijs Westerman, Aart Beeker, A. Meerveld-Eggink, Ger T. Rijkers, Douwe H. Biesma	12
13	Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria 2012 ·European Journal of Clinical Microbiology & Infectious Diseases ·Evelyn Peelen, Ger T. Rijkers, A. Meerveld-Eggink, Sabine C A Meijvis, Mario H. J. Vogt, J. W. Cohen Tervaert, Raymond Hupperts, Jan Damoiseaux	27
14	Voorkomen van ernstige infecties bij patienten met hypo- of asplenie 2012 ·Data Archiving and Networked Services (DANS) ·(unknown), Nicoline van der Maas, Edgar J.G. Peters, A. Meerveld-Eggink, E. A. M. Sanders, Frank P. Kroon	2
15	[Prevention of severe infections in patients with hyposplenism or asplenia]. 2012 ·PubMed ·(unknown), Nicoline van der Maas, Edgar Peters, A. Meerveld-Eggink, Elisabeth A. M. Sanders, Frank P. Kroon, (unknown)	4
16	Response to influenza virus vaccination during chemotherapy in patients with breast cancer 2011 ·Annals of Oncology ·A. Meerveld-Eggink, Okke de Weerdt, Ankie M.T. van der Velden, Maartje Los, Annette W.G. van der Velden, Jacqueline M. Stouthard, Marten R. Nijziel, Matthijs Westerman, Aart Beeker, Ruud van Beek, Guus F. Rimmelzwaan, Ger T. Rijkers, Douwe H. Biesma	45
17	Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients 2010 ·Vaccine ·A. Meerveld-Eggink, Okke de Weerdt, Heleen van Velzen‐Blad, Douwe H. Biesma, Ger T. Rijkers	24
18	Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients 2010 ·European Journal of Clinical Microbiology & Infectious Diseases ·A. Meerveld-Eggink, Okke de Weerdt, Richarda M. de Voer, Guy A. M. Berbers, Heleen van Velzen‐Blad, Bart J. M. Vlaminckx, Douwe H. Biesma, Ger T. Rijkers	16
19	Antibody Response to Polysaccharide Conjugate Vaccines after Nonmyeloablative Allogeneic Stem Cell Transplantation 2009 ·Biology of Blood and Marrow Transplantation ·A. Meerveld-Eggink, Ankie M.T. van der Velden, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Douwe H. Biesma, Ger T. Rijkers	22
20	Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in the Netherlands 2008 ·Vaccine ·A. Meerveld-Eggink, Okke de Weerdt, Ger T. Rijkers, Heleen van Velzen‐Blad, Douwe H. Biesma	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact